Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-04 EST			5-day change	1st Jan Change
9.850 ^USD	+12.06%		+12.83%	-12.44%

11-15	Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment	MT
11-15	Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Altimmune, Inc.

Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment	11-15	MT
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024	11-15	CI
Altimmune, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 09:30 AM	11-13
Altimmune, Inc., Q3 2024 Earnings Call, Nov 12, 2024	11-12
Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $5,000	11-12	MT
UBS Initiates Altimmune at Buy With $26 Price Target	11-12	MT
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-12	CI
Altimmune Names Greg Weaver Chief Financial Officer	11-11	MT
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer	11-11	CI
Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity	11-07	CI
Altimmune Completes Enrollment for Phase 2b Trial of Pemvidutide in Chronic Liver Disease	09-30	MT
Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	09-30	CI
Sector Update: Health Care Stocks Advance Late Afternoon	09-10	MT
Altimmune Shares Jump After Pemvidutide Shows Strong Lean Mass Preservation in Obesity Trial	09-10	MT
Altimmune, Inc. Announces That David J. Drutz Will Not Stand for Re-Election to the Board	08-15	CI
Altimmune, Inc., Q2 2024 Earnings Call, Aug 08, 2024	08-08
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Revenue $5,000	08-08	MT
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Loss $-0.35 Per Share, vs. Street Est of Loss $-0.35 Per Share	08-08	MT
Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-08	CI
Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease in Journal of Hepatology	07-25	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000 Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell Microcap Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000E Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2000 Growth Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2500 Growth Index	06-30	CI

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-12-06 - Society on Sarcopenia Cachexia & Wasting Disorders International Conference

More about the company